OnKure Therapeutics (OKUR) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed OnKure Therapeutics (OKUR) over the past year, gaining 40.0% versus a loss of 23.0%. Over five years, PDSB leads with a -88.8% price change compared with -96.3% for OKUR. PDS Biotechnology is the larger company by market cap ($100.0 million vs $97.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKUR | PDSB |
|---|---|---|
| Share price | $2.41 | $1.38 |
| Market cap | $97.60M | $100.01M |
| 1-day change | +4.78% | +35.29% |
| YTD return | -16.90% | +79.22% |
| 1-year return | -23.00% | +39.96% |
| 5-year return | -96.26% | -88.81% |
| EPS (TTM) | $-3.20 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.38 | $1.55 |
| 52-week low | $2.13 | $0.195 |
| Distance from 52-week high | -55.20% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +543.15% | +262.32% |
| Average volume | 216.96K | 23.24M |
| Shares outstanding | 40.50M | 72.47M |
| Employees | 45 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed OKUR by 63.0 percentage points over the past year.
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
OKUR vs PDSB FAQ
Which is bigger, OnKure Therapeutics or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $97.60M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, OKUR or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -23.00% for OKUR (price return, excluding dividends). Past performance does not predict future results.
Are OnKure Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.